Did you know that your version of Internet Explorer is out of date?
To get the best possible experience using our website we recommend downloading one of the browsers below.
Internet Explorer 10, Firefox, Chrome, or Safari.
The pan-Canadian Pharmaceutical Alliance (pCPA) is an alliance of public drug program leaders from all provincial, territorial and federal governments. pCPA members work collaboratively to negotiate drug prices for their respective programs. Its pricing decisions are a precondition of having a medication covered on public drug formularies.
When a drug comes to Canada it must go through the Canadian drug regulatory, review and reimbursement system. The drug must go to various review bodies before it is eligible for public reimbursement. The pCPA is the second last stage before public health plans decide whether or not to list a drug. Successful negotiations through the pCPA then have to go through a final review by all public drug programs.
In 2019, the pCPA and the manufacturer completed price negotiations for additional Kalydeco mutations, and Kalydeco was included in the agreement struck between the manufacturer and the pCPA in 2021, as well as Orkambi, for all Health Canada approved mutations. Trikafta was added to this agreement for those 12+shortly after this deal was struck, upon Health Canada approval and positive cost-effectiveness studies. This agreement was amended in 2022 to include those who are 6+ and indicated for the drug.
Most Canadian jurisdictions now provide broader, albeit still limited, access to Kalydeco and Orkambi, and broad access to Kalydeco for those six years of age or older with at least one copy of the F508del mutation. People with rarer and ultra-rare mutations that can be treated by Trikafta and other modulators have not yet been indicated by Health Canada.
Cystic Fibrosis Canada is working to ensure that anyone who can benefit from a modulator can get one.
It amended the agreement signed with Vertex for Trikafta for the 12+ age group in 2021 to include those 6 years of age and older who have at least one copy of the F508del mutation.
Are you curious about the challenges and complexities faced by individuals with cystic fibrosis (CF) as they age? Join us for a webinar for the Canadian CF community featuring Dr. Anne Stephenson, Medical Director Canadian Cystic Fibrosis Registry and CF Physician at St. Michael's Hospital.
When: September 25 from 7-8 pm ET
Where: Zoom
.png)
Gillian Maramieri has been involved with Cystic Fibrosis Canada for 10 years and is a working mother of two boys. Her youngest, Matthew, has cystic fibrosis and was the first to be diagnosed with CF in the family. He was diagnosed at birth after Gillian’s doctors noticed an echogenic bowel 18 weeks into her pregnancy. Her first words after the diagnosis were, "Ok, now what do we need to do?"
Read More
